Chimeric Antigen Receptor T-cell (CAR-T) therapy continues to redefine the landscape of advanced treatments. Since the first FDA approvals in 2017, the field has witnessed a surge in innovation, with new CAR-T products entering clinical trials and expanding the boundaries of what is possible in cell and gene therapy.